• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Novo Nordisk A/S

    3/31/25 6:00:08 AM ET
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVO alert in real time by email
    6-K 1 f6k_032725.htm FORM 6-K

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    ________________

     

    FORM 6-K

    ________________

     

    REPORT OF FOREIGN PRIVATE ISSUER

     

    Pursuant to Rule 13a-16 or 15d-16

    of the Securities Exchange Act of 1934

     

    March 27, 2025

    ________________

     

    NOVO NORDISK A/S

     (Exact name of Registrant as specified in its charter)

     

     

    Novo Allé 1

    DK- 2880, Bagsvaerd

    Denmark

    (Address of principal executive offices)

    ________________

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

     

    Form 20-F ☒           Form 40-F ☐

      

     
     

     

     

     

     

     

    Resolutions from for the Annual General Meeting of Novo Nordisk A/S

     

    Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting.

     

    At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “2024 was another year of significant growth for Novo Nordisk, characterised by continued innovation, capacity expansions and commercial execution. Our industry-leading therapeutic innovations benefited more than 45 million people living with diabetes and obesity worldwide. As we strive to keep pace with increasing demand, we continue to invest in scaling up our manufacturing capabilities, and we are building capacity to serve millions more patients.”

     

    Resolutions adopted at the Annual General Meeting

    Financial year 2024 and remuneration

    • Approval of the Company’s statutory Annual Report 2024 and distribution of profits according to the statutory Annual Report 2024.

    • The final dividend for 2024 of DKK 7.90 for each Novo Nordisk A and B share of DKK 0.10. The total dividend for 2024 of DKK 11.40 includes both the interim dividend of DKK 3.50 for each Novo Nordisk A and B share of DKK 0.10, which was paid in August 2024, and the final dividend of DKK 7.90 for each Novo Nordisk A and B share of DKK 0.10 to be paid in March 2025.

    • Approval of the Remuneration Report 2024 (advisory vote) and of the remuneration of the Board of Directors for 2025.

     

    Elections

    • Re-election of Helge Lund as chair of the Board of Directors.

    • Re-election of Henrik Poulsen as vice chair of the Board of Directors.

    • Re-election of Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, Kasim Kutay and Martin Mackay as members of the Board of Directors

     

     

    Page 2 of 3

    • Appointment of Deloitte Statsautoriseret Revisionspartnerselskab as the Company’s auditor in respect of statutory financial and sustainability reporting.

     

    Shares and capital

    • Authorisation to the Board of Directors until the Annual General Meeting 2026 to allow the Company to repurchase own shares of up to 10% of the share capital subject to a holding limit of 10% of the share capital.

    • Extension of the authorisation to the Board of Directors to increase the Company's share capital for a period of one year until 1 April 2027 up to nominally DKK 44,650,000.

    • A shareholder proposal on construction contracts was not approved.

     

    The meeting was held as a hybrid meeting, enabling shareholders to participate either in person or virtually. The shareholders were encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.

     

    Composition of the Board of Directors and its committees

    After the Annual General Meeting, the Board of Directors held a board meeting to appoint members of its committees.

     

    The Board of Directors, including its committees, is now composed as follows:

    • Helge Lund (chair of the Board and chair of the People and Governance Committee)
    • Henrik Poulsen (vice chair of the Board, chair of the Remuneration Committee and member of the Audit Committee)
    • Elisabeth Dahl Christensen (employee-elected board member and member of the Remuneration Committee)
    • Laurence Debroux (chair of the Audit Committee and member of the Remuneration Committee)
    • Andreas Fibig (member of the Research & Development Committee)
    • Sylvie Grégoire (member of the Audit Committee, the People and Governance Committee and the Research & Development Committee)
    • Liselotte Hyveled (employee-elected board member and member of the Research & Development Committee)
    • Mette Bøjer Jensen (employee-elected board member and member of the Audit Committee)
    • Kasim Kutay (member of the People and Governance Committee and the Research & Development Committee)
    • Christina Law (member of the Audit Committee and the People and Governance Committee)
    • Martin Mackay (chair of the Research & Development Committee and member of the Remuneration Committee)
    • Thomas Rantzau (employee-elected board member and member of the People and Governance Committee)

     

     

     

    Page 3 of 3

     

    Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

     

    Contacts for further information

     

    Media:  

    Ambre James-Brown

    +45 3079 9289

    [email protected]

    Liz Skrbkova (US)

    +1 609 917 0632

    [email protected]

       
    Investors:  

    Jacob Martin Wiborg Rode

    +45 3075 5956

    [email protected]

    Ida Schaap Melvold

    +45 3077 5649

    [email protected]

       

    Sina Meyer

    +45 3079 6656

    [email protected]

    Max Ung

    +45 3077 6414

    [email protected]

       

    Frederik Taylor Pitter

    +1 609 613 0568

    [email protected]

     

     

     

     

     

     

    Novo Nordisk A/S

    Investor Relations

    Novo Allé 1

    2880 Bagsværd

    Denmark

    Telephone:

    +45 4444 8888

    www.novonordisk.com
    CVR no: 24 25 67 90

       Company announcement No 12 / 2025

     
     

    SIGNATURES

     

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

     

    Date: March 27, 2025

     

    NOVO NORDISK A/S

     

    Lars Fruergaard Jørgensen

    Chief Executive Officer

     

     

     

     

     

     

     

     

     

     

    Get the next $NVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVO

    DatePrice TargetRatingAnalyst
    4/17/2025$64.00Outperform → Market Perform
    BMO Capital Markets
    3/13/2025Hold → Buy
    Kepler
    3/3/2025Buy → Hold
    Stifel
    2/12/2025Equal-Weight
    Morgan Stanley
    1/6/2025Underperform → Mkt Perform
    Bernstein
    5/30/2024$156.00Buy
    Goldman
    4/12/2024$163.00Outperform
    BMO Capital Markets
    1/23/2024$120.00Overweight
    Morgan Stanley
    More analyst ratings

    $NVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Novo Nordisk A/S downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Novo Nordisk A/S from Outperform to Market Perform and set a new price target of $64.00

      4/17/25 8:30:12 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S upgraded by Kepler

      Kepler upgraded Novo Nordisk A/S from Hold to Buy

      3/13/25 8:17:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk A/S downgraded by Stifel

      Stifel downgraded Novo Nordisk A/S from Buy to Hold

      3/3/25 7:34:14 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer

      The Wegovy® savings offer is good for all dose strengths of Wegovy® Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choicePLAINSBORO, N.J., March 24, 2025 /PRNewswire/ -- Today, Novo Nordisk announced updates to the Wegovy® savings program, allowing all eligible cash-paying patients access to Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg at their local pharmacy for a reduced cost of $499 per month. Until today, the $499-per-month offer for Wegovy® was only available via the recently launched NovoCare® Pharmacy. "At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them acces

      3/24/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients

      NovoCare® Pharmacy provides direct-to-patient, convenient home shipments of all dose strengths of Wegovy® at a reduced cost of $499 per month for cash-paying patients While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was designed to support cash-paying patients without insurance coverageAmidst the dangers of fake or illegitimate compounded "semaglutide," NovoCare® Pharmacy offers reliable access to authentic, FDA-approved Wegovy® in our once-weekly, single-dose pen PLAINSBORO, N.J., March 5, 2025 /PRNewswire/ -- As part of its ongoing efforts to ensure patients who need Wegovy® (semaglutide) injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg can access i

      3/5/25 8:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Defiance Launches NVOX, the First 2X Leveraged Single-Stock ETF on Novo Nordisk

      MIAMI, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Defiance ETFs today launched NVOX, the world's first single-stock leveraged ETF for the pharmaceutical stock Novo Nordisk (NYSE:NVO). As the weight loss market continues to expand and Novo Nordisk is a key provider in that space, NVOX offers retail investors 2X daily long leveraged exposure to the change in the daily share price of Novo Nordisk without the need for a margin account. This provides a unique tool for tactical traders. NVOX does not invest directly in Novo Nordisk and has a higher degree of risk due to tracking a single stock. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark, seeking to

      12/3/24 6:00:00 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 8, 2024 - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration approved a new indication for use for Wegovy (semaglutide) injection to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight. Wegovy should be used in addition to a reduced calorie diet and increased physical activity. Cardiovascular disease is a gr

      3/8/24 2:00:18 PM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/9/25 8:12:45 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      5/7/25 8:01:16 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Novo Nordisk A/S

      6-K - NOVO NORDISK A S (0000353278) (Filer)

      4/3/25 6:05:06 AM ET
      $NVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • EXL Announces Appointment of Andreas Fibig to Board of Directors

      NEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ExlService Holdings, Inc. (NASDAQ:EXLS), a leading global data analytics and digital operations and solutions company, today announced that Andreas Fibig, a seasoned global executive with a strong record of innovation across industries and geographies, has been appointed to EXL's Board of Directors as an independent director effective Jan. 10, 2023. Fibig will be a member of the Board's Audit and Nominating and Governance Committees. "Andreas is a distinguished global business leader with more than 25 years of international health care, pharmaceutical, and consumer industry experience," said Vikram S. Pandit, Chairman of the Board of EXL. "We lo

      1/12/23 4:01:00 PM ET
      $EXLS
      $IFF
      $NVO
      Business Services
      Consumer Discretionary
      Major Chemicals
      Industrials
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals